Tatsuya Fujinami1,2, Takashi Ashikaga3, Katsuyuki Hoshina4, Taro Sasaoka5, Ken Kurihara6, Shunji Yoshikawa7, Hiroshi Inagaki8, Tetsuo Sasano9. 1. Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan. 2. Department of Cardiology, Toshima Hospital, Tokyo, Japan. 3. Department of Cardiology, Musashino Red Cross Hospital, Tokyo, Japan. 4. Department of Vascular Surgery, The University of Tokyo, Tokyo, Japan. 5. Kamiigusa Clinic, Tokyo, Japan. 6. Department of Cardiology, Ome Municipal General Hospital, Tokyo, Japan. 7. Department of Cardiology, Tokyo Yamate Medical Center, Tokyo, Japan. 8. Department of Cardiology, Soka Municipal Hospital, Saitama, Japan. 9. Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan; sasano.bi@tmd.ac.jp.
Abstract
BACKGROUND/AIM: The effect of β-adrenergic blockers on everolimus-eluting stent (EES) implantation is unknown. We aimed to investigate how β-blockers affect the outcomes of EES by using the Tokyo-MD PCI registry data and analyse real-world data in this drug-eluting stent era in Japan. PATIENTS AND METHODS: We selected 1,899 patients who underwent EES implantation. We compared patients with β-blocker administration versus those without, at follow-up regarding the incidence rate of ischemia-driven target lesion revascularization (ID-TLR), all-cause death, cardiac death, acute myocardial infarction (AMI), and stent thrombosis (ST). RESULTS: Patients in the β-blocker group had higher coronary risks than those in the non-β-blocker group. Although no significant difference was observed in the five-year incidence of all-cause death, cardiac death, AMI, and ST between the two groups, the incidence of ID-TLR was significantly lower in the β-blocker group (4.5% vs. 6.6%; p=0.04). β-Blocker administration (hazard ratio=0.61; p=0.016) was negatively associated with ID-TLR via multivariate analysis. CONCLUSION: β-Blocker administration reduced ID-TLR after percutaneous coronary intervention using an EES despite the greater comorbid risks and more severe disease lesions.
BACKGROUND/AIM: The effect of β-adrenergic blockers on everolimus-eluting stent (EES) implantation is unknown. We aimed to investigate how β-blockers affect the outcomes of EES by using the Tokyo-MD PCI registry data and analyse real-world data in this drug-eluting stent era in Japan. PATIENTS AND METHODS: We selected 1,899 patients who underwent EES implantation. We compared patients with β-blocker administration versus those without, at follow-up regarding the incidence rate of ischemia-driven target lesion revascularization (ID-TLR), all-cause death, cardiac death, acute myocardial infarction (AMI), and stent thrombosis (ST). RESULTS: Patients in the β-blocker group had higher coronary risks than those in the non-β-blocker group. Although no significant difference was observed in the five-year incidence of all-cause death, cardiac death, AMI, and ST between the two groups, the incidence of ID-TLR was significantly lower in the β-blocker group (4.5% vs. 6.6%; p=0.04). β-Blocker administration (hazard ratio=0.61; p=0.016) was negatively associated with ID-TLR via multivariate analysis. CONCLUSION: β-Blocker administration reduced ID-TLR after percutaneous coronary intervention using an EES despite the greater comorbid risks and more severe disease lesions.
Authors: Srihari S Naidu; Mitchell W Krucoff; David R Rutledge; Vivian W Mao; Weiying Zhao; Qing Zheng; Olivia Wilburn; Krishnankutty Sudhir; Charles Simonton; James B Hermiller Journal: JACC Cardiovasc Interv Date: 2012-06 Impact factor: 11.195
Authors: Jeffrey L Anderson; Cynthia D Adams; Elliott M Antman; Charles R Bridges; Robert M Califf; Donald E Casey; William E Chavey; Francis M Fesmire; Judith S Hochman; Thomas N Levin; A Michael Lincoff; Eric D Peterson; Pierre Theroux; Nanette Kass Wenger; R Scott Wright; Sidney C Smith Journal: Circulation Date: 2011-03-28 Impact factor: 29.690
Authors: Gregg W Stone; Jeffrey W Moses; Stephen G Ellis; Joachim Schofer; Keith D Dawkins; Marie-Claude Morice; Antonio Colombo; Erick Schampaert; Eberhard Grube; Ajay J Kirtane; Donald E Cutlip; Martin Fahy; Stuart J Pocock; Roxana Mehran; Martin B Leon Journal: N Engl J Med Date: 2007-02-12 Impact factor: 91.245
Authors: P W Serruys; P de Jaegere; F Kiemeneij; C Macaya; W Rutsch; G Heyndrickx; H Emanuelsson; J Marco; V Legrand; P Materne Journal: N Engl J Med Date: 1994-08-25 Impact factor: 91.245
Authors: Jeffrey W Moses; Martin B Leon; Jeffrey J Popma; Peter J Fitzgerald; David R Holmes; Charles O'Shaughnessy; Ronald P Caputo; Dean J Kereiakes; David O Williams; Paul S Teirstein; Judith L Jaeger; Richard E Kuntz Journal: N Engl J Med Date: 2003-10-02 Impact factor: 91.245